Breaking News

Financial Report: WuXi Pharma Tech 3Q

November 13, 2012

Lab Services up 26%, driven by China-based labs

WuXi Pharma Tech

3Q Revenues: $125.8 million (+21%)

3Q Earnings: $213 million (+3%)

YTD Revenues: $374.3 million (+25%)

YTD Earnings: $62.8 million (+9%)

Comments: Laboratory Services were $98.9 million in the quarter, up 26%. China-based Lab Services increased 32% to $77.0 million. U.S.-based Lab Services were up 6% to $21.9 million. Manufacturing services were $26.9 million, up 7%.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision